Instylla is a privately held company based in Bedford, MA, focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis. The company’s first product, Embrace™ Hydrogel Embolic System, is designed for controlled, complete, and persistent embolization in these clinical conditions.

Instylla was founded in 2017 by Incept LLC and is funded by several leading venture capital groups.